Novartis hat scheinbar mit ihrem Medikament ein großes Problem (aktuell in Japan), das könnte sich auf Ariad positiv auswirken. Die Sommerpause ist vorbei…
---
Novartis fails to report side effects, fatality in Japan. "How many were hidden in US clinical trials?" asked greggors .
Novartis fails to report side effects, fatality, 6:52 pm, August 30, 2014. Jiji Press
Novartis Pharma K.K. said it has failed to report to the health ministry at least 2,579 cases of serious side effects, including a fatality, from its drugs for leukemia and other diseases even though its employees were aware of the problems.
Of the total, 1,313 cases were related to Glivec and 514 cases to Tasigna, both drugs for leukemia treatment, and 261 cases involved cancer drug Afinitor, said the Japanese unit of Swiss drug giant Novartis AG on Friday.
The findings were reported to the Health, Labor and Welfare Ministry the same day.
Marketing employees at the firm had recognized the side effects, but failed to report them to its division in charge in violation of its internal rules, Novartis Pharma said. They were not fully aware of the seriousness of the problem, while higher-ranking officials failed to supervise them properly, it said.
---
If you see a mouse you will find a nest.... I believe there is more to come to the surface very soon .... In time I wouldn't have been surprised if Novartis try to change the course of ariad .... Direct or indirectly influencing ..... Money buys a lot in business even at any cost ...... They could have been hiding this for multiple reasons ... So don't get me started on all the strategic possibilities ... But this isn't looking good anymore for Novartis and justice will reveal all this by itself in the very near future .... But now this will only increasing the attention to Ariad as it is best in class .... Wouldn't this not speed up partnerships or possible buyouts .... I would say yes but not for a ridiculous low price .... So shorts running out of steam very soon
finance.yahoo.com/mbview/threadview/...5&mbtc=mb-tab-topic